Posted by Michael Wonder on 27 Nov 2025
Alvotech announces approval of AVT03, a biosimilar to Prolia and Xgeva (denosumab) in the European Economic Area
November 24, 2025 - Alvotech today announced that the European Commission has approved AVT03 as a biosimilar to Prolia and Xgeva (denosumab).
In Europe, AVT03 will be marketed in partnerships with STADA and Dr. Reddy's, where each partner holds semi-exclusive rights in the EEA, Switzerland and the UK.
